Renal-nerve ablation in patients with resistant hypertension. Caution is still needed.;Dénervation rénale endovasculaire par radiofréquence dans l'hypertension artérielle résistante. La prudence reste encore de mise à ce jour.

Presse Medicale

Volumn 41, Issue 4, 2012, Pages 349-357

  Steichen, Olivier ^a,b   Sapoval, Marc ^a,b   Frank, Michael ^c   Bobrie, Guillaume ^b   Plouin, Pierre François ^a,b   Azizi, Michel ^a,b,c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; DIURETIC AGENT;

ABLATION THERAPY; ADVERSE OUTCOME; AUTONOMIC NERVOUS SYSTEM FUNCTION; BLOOD PRESSURE FLUCTUATION; BLOOD PRESSURE REGULATION; CATHETERIZATION; DRUG EFFICACY; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; HUMAN; HYPERTENSION; KIDNEY DENERVATION; MORTALITY; OPTIMAL DRUG DOSE; SHORT SURVEY; SYMPATHECTOMY;

ADULT; ANTIHYPERTENSIVE AGENTS; CATHETER ABLATION; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; FRANCE; HUMANS; HYPERTENSION, RENOVASCULAR; KIDNEY; MALE; RENAL ARTERY; SYMPATHECTOMY;

EID: 84858748133     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2011.05.009     Document Type: Short Survey

References (28)

1. Esler M.D., Krum H., Sobotka P.A., Schlaich M.P., Schmieder R.E., Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010, 376:1903-1909.
2. Krum H., Schlaich M., Whitbourn R., Sobotka P.A., Sadowski J., Bartus K., et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009, 373:1275-1281.
3. DiBona G.F., Esler M. Translational medicine: the antihypertensive effect of renal denervation. Am J Physiol Regul Integr Comp Physiol 2010, 298:R245-R253.
4. Schlaich M.P., Sobotka P.A., Krum H., Whitbourn R., Walton A., Esler M.D. Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. Hypertension 2009, 54:1195-1201.
5. Page I.H., Heuer G.J. A surgical treatment of essential hypertension. J Clin Invest 1935, 14:22-26.
6. Peet M.M. Hypertension and its surgical treatment by bilateral supradiaphragmatic splanchnicectomy. Am J Surg 1948, 75:48-68.
7. Smithwick R.H., Thompson J.E. Splanchnicectomy for essential hypertension; results in 1266cases. J Am Med Assoc 1953, 152:1501-1504.
8. Doumas M., Faselis C., Papademetriou V. Renal sympathetic denervation and systemic hypertension. Am J Cardiol 2010, 105:570-576.
9. Godet-Thobie H., Vernay M., Noukpoape A., Salanave B., Malon A., Castetbon K., et al. Niveau tensionnel moyen et prévalence de l'hypertension artérielle chez les adultes de 18 à 74ans, ENNS 2006-2007. BEH 2008, 49-50:478-483.
10. Samsons S., Ricordeau P., Pepin S., Tilly B., Weill A., Alleman H. Hypertension artérielle et facteurs de risque associés : évolution des traitements entre 2000 et 2006. Point Rep 2007, 10:1-8.
11. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo J.L., et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003, 42:1206-1252.
12. Haute Autorité de santé Prise en charge des patients adultes atteints d'hypertension artérielle essentielle, actualisation 2005. J Mal Vasc 2006, 31:16-33.
13. Mancia G., De Backer G., Dominiczak A., Cifkova R., Fagard R., Germano G., et al. 2007 ESH-ESC practice guidelines for the management of arterial hypertension: ESH-ESC task force on the management of arterial hypertension. J Hypertens 2007, 25:1751-1762.
14. Calhoun D.A., Jones D., Textor S., Goff D.C., Murphy T.P., Toto R.D., et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for high blood pressure research. Hypertension 2008, 51:1403-1419.
15. Sarafidis P.A., Bakris G.L. Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol 2008, 52:1749-1757.
16. Frank M., Bobrie G., Azizi M., Peyrard S., Plouin P.F. Clinical profile of patients referred to a tertiary hypertension unit in a city area. J Hypertens 2010, 28:e264.
17. Persell S.D. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension 2011, 57:1076-1080.
18. Calhoun D.A., Lacourciere Y., Chiang Y.T., Glazer R.D. Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial. Hypertension 2009, 54:32-39.
19. de la Sierra A., Segura J., Banegas J.R., Gorostidi M., de la Cruz J.J., Armario P., et al. Clinical features of 8295patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011, 57:898-902.
20. Scheffers I.J., Kroon A.A., Schmidli J., Jordan J., Tordoir J.J., Mohaupt M.G., et al. Novel baroreflex activation therapy in resistant hypertension: results of a European multicenter feasibility study. J Am Coll Cardiol 2010, 56:1254-1258.
21. Symplicity HTN-1, Investigators Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24months. Hypertension 2011, 57:911-917.
22. Esler M., Schlaich M., Sobotka P., Whitbourn R., Sadowski J., Bartus K., et al. Catheter-based renal denervation reduces total body and renal noradrenaline spillover and blood pressure in resistant hypertension. J Hypertens 2009, 27:S167.
23. Schlaich M.P., Sobotka P.A., Krum H., Lambert E., Esler M.D. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009, 361:932-934.
24. Doumas M., Douma S. Renal sympathetic denervation: the jury is still out. Lancet 2010, 376:1878-1880.
25. DiBona G.F. Renal innervation and denervation: lessons from renal transplantation reconsidered. Artif Organs 1987, 11:457-462.
26. Chapman N., Dobson J., Wilson S., Dahlof B., Sever P.S., Wedel H., et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007, 49:839-845.
27. Schlaich M.P., Straznicky N., Grima M., Ika-Sari C., Dawood T., Mahfoud F., et al. Renal denervation: a potential new treatment modality for polycystic ovary syndrome?. J Hypertens 2011, 29:991-996.
28. Barkun J.S., Aronson J.K., Feldman L.S., Maddern G.J., Strasberg S.M., Altman D.G., et al. Evaluation and stages of surgical innovations. Lancet 2009, 374:1089-1096.